TY - JOUR T1 - Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials JF - medRxiv DO - 10.1101/2021.05.03.21256468 SP - 2021.05.03.21256468 AU - Azita H. Talasaz AU - Parham Sadeghipour AU - Maryam Aghakouchakzadeh AU - Isaac Dreyfus AU - Hessam Kakavand AU - Hamid Ariannejad AU - Aakriti Gupta AU - Mahesh V. Madhavan AU - Benjamin W. Van Tassell AU - David Jimenez AU - Manuel Monreal AU - Muthiah Vaduganathan AU - John Fanikos AU - Dave L Dixon AU - Gregory Piazza AU - Sahil A. Parikh AU - Deepak L. Bhatt AU - Gregory YH Lip AU - Gregg W. Stone AU - Harlan M. Krumholz AU - Peter Libby AU - Samuel Z. Goldhaber AU - Behnood Bikdeli Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/05/2021.05.03.21256468.abstract N2 - Coronavirus disease 2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multi-organ manifestations. Lipid modulating agents may be useful in treating patients with COVID-19. They may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglycerides portends worse outcome in patients with COVID-19. Upon a systematic search, 40 RCTs with lipid modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for management or prevention of COVID-19. This manuscript summarizes the ongoing or completed randomized controlled trials (RCTs) of lipid modulating agents in COVID-19 and the implications of these trials for patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability only after permission of corresponding authorACE2angiotensin converting enzyme 2ARDSacute respiratory distress syndromeCETPcholesterol ester transfer proteinCOVID-19coronavirus disease 2019HDLhigh-density lipoproteinHMG-CoA3-hydroxy-3-methyl-glutaryl-coenzyme AICUintensive care unitNADnicotinamide adenine dinucleotideRCTrandomized controlled trialSARS-CoV-2severe acute respiratory syndrome coronavirus 2 ER -